Scientists reviewed 21 clinical trials across 60 manuscripts that featured a Food and Drug Administration-approved CAR T-cell construct or one of its predecessors. They highlighted substantial variability and limited reporting of cytokine measurement platforms and panels used across CAR T-cell clinical trials.
[Molecular Therapy]
